Literature DB >> 24791755

Borderline personality disorder and comorbid addiction: epidemiology and treatment.

Thorsten Kienast1, Jutta Stoffers, Felix Bermpohl, Klaus Lieb.   

Abstract

BACKGROUND: Borderline personality disorder (BPD) affects 2.7% of adults. About 78% of adults with BPD also develop a substance-related disorder or addiction at some time in their lives. These persons are more impulsive and clinically less stable than BPD patients without substance dependency. They display suicidal behavior to a greater extent, drop out of treatment more often, and have shorter abstinence phases. The combination of borderline personality disorder with addiction requires a special therapeutic approach.
METHOD: This review is based on a selective literature search about the treatment of patients with BPD and addiction, with particular attention to Cochrane Reviews and randomized controlled trials (RCT).
RESULTS: The available evidence is scant. In two RCTs, Dialectical Behavior Therapy for Substance Use Disorders (DBT-SUD) was found to improve patients' overall functional level (standardized mean difference, 1.07-1.78) and to increase the number of abstinence days (effect strength [ES], 1.03) and negative urine samples (ES, 0.75). Dual focus schema therapy (DFST) was evaluated in three RCTs. Because of methodological problems, however, no useful quantitative comparison across trials is possible. In one RCT, dynamic deconstructive psychotherapy (DDP) was found to have only a moderate, statistically insignificant effect. Only a single study provides data about potentially helpful drug therapy over the intermediate term.
CONCLUSION: Patients with borderline personality disorder and comorbid addiction should be treated as early as possible for both conditions in a thematically hierarchical manner. There is no evidence for any restriction on drug therapy to prevent recurrent addiction in these patients. The psychotherapeutic techniques that can be used (despite the currently inadequate evidence base) include DBT-SUD, DFST, and DDP. These patients need qualified expert counseling in choosing a suitable type of psychotherapy. Specific treatment is available in only a few places, and the relevant treatment networks in Germany are just beginning to be constructed.

Entities:  

Mesh:

Year:  2014        PMID: 24791755      PMCID: PMC4010862          DOI: 10.3238/arztebl.2014.0280

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  30 in total

1.  A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder: six-month outcome.

Authors:  Robert J Gregory; Anna L Remen; Maureen Soderberg; Robert J Ploutz-Snyder
Journal:  J Am Psychoanal Assoc       Date:  2009-02

2.  Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occurring with alcohol use disorders: a 30-month follow-up.

Authors:  Robert J Gregory; Evan DeLucia-Deranja; Jacqueline A Mogle
Journal:  J Nerv Ment Dis       Date:  2010-04       Impact factor: 2.254

3.  The impact of borderline personality disorder on residential substance abuse treatment dropout among men.

Authors:  Matthew T Tull; Kim L Gratz
Journal:  Drug Alcohol Depend       Date:  2011-09-09       Impact factor: 4.492

4.  Substance abuse and personality disorders in homeless drop-in center clients: symptom severity and psychotherapy retention in a randomized clinical trial.

Authors:  Samuel A Ball; Patricia Cobb-Richardson; Adrian J Connolly; Cesar T Bujosa; Thomas W O'neall
Journal:  Compr Psychiatry       Date:  2005 Sep-Oct       Impact factor: 3.735

5.  Personality disorder and chronicity of addiction as independent outcome predictors in alcoholism treatment.

Authors:  Henning Krampe; Thilo Wagner; Sabina Stawicki; Claudia Bartels; Carlotta Aust; Birgit Kroener-Herwig; Heinrich Kuefner; Hannelore Ehrenreich
Journal:  Psychiatr Serv       Date:  2006-05       Impact factor: 3.084

6.  Randomized trial of dual-focused vs. single-focused individual therapy for personality disorders and substance dependence.

Authors:  Samuel A Ball; Lisa M Maccarelli; Donna M LaPaglia; Mark J Ostrowski
Journal:  J Nerv Ment Dis       Date:  2011-05       Impact factor: 2.254

7.  Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; D Bradford Reich; Kenneth R Silk
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

Review 8.  [Application of dialectical behavior therapy as in-patient treatment for alcohol dependency].

Authors:  F Mayer-Bruns; K Lieb; E Dannegger; G A Jacob
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

9.  Axis I comorbidity of borderline personality disorder.

Authors:  M C Zanarini; F R Frankenburg; E D Dubo; A E Sickel; A Trikha; A Levin; V Reynolds
Journal:  Am J Psychiatry       Date:  1998-12       Impact factor: 18.112

Review 10.  Manualized treatment for substance abusers with personality disorders: dual focus schema therapy.

Authors:  S A Ball
Journal:  Addict Behav       Date:  1998 Nov-Dec       Impact factor: 3.913

View more
  13 in total

1.  The relationship between dispositional mindfulness, borderline personality features, and suicidal ideation in a sample of women in residential substance use treatment.

Authors:  Ryan C Shorey; JoAnna Elmquist; Caitlin Wolford-Clevenger; Michael J Gawrysiak; Scott Anderson; Gregory L Stuart
Journal:  Psychiatry Res       Date:  2016-02-17       Impact factor: 3.222

2.  Comparison of treatment outcomes in severe personality disorder patients with or without substance use disorders: a 36-month prospective pragmatic follow-up study.

Authors:  Fernando Lana; Carmen Sánchez-Gil; Núria D Adroher; Víctor Pérez; Guillem Feixas; Josep Martí-Bonany; Marta Torrens
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-21       Impact factor: 2.570

3.  Comorbidity study of borderline personality disorder: applying association rule mining to the Taiwan national health insurance research database.

Authors:  Cheng-Che Shen; Li-Yu Hu; Ya-Han Hu
Journal:  BMC Med Inform Decis Mak       Date:  2017-01-11       Impact factor: 2.796

4.  Relationship between borderline personality symptoms and Internet addiction: The mediating effects of mental health problems.

Authors:  Wei-Hsin Lu; Kun-Hua Lee; Chih-Hung Ko; Ray C Hsiao; Huei-Fan Hu; Cheng-Fang Yen
Journal:  J Behav Addict       Date:  2017-08-29       Impact factor: 6.756

5.  Criminalization Through Transinstitutionalization: A Critical Review of the Penrose Hypothesis in the Context of Compensation Imprisonment.

Authors:  Sebastian Schildbach; Carola Schildbach
Journal:  Front Psychiatry       Date:  2018-10-25       Impact factor: 4.157

Review 6.  Comorbidity of Personality Disorder among Substance Use Disorder Patients: A Narrative Review.

Authors:  Arpit Parmar; Gaurishanker Kaloiya
Journal:  Indian J Psychol Med       Date:  2018 Nov-Dec

7.  Depressive Symptoms and Addictive Behaviors in Young Adults After Childhood Trauma: The Mediating Role of Personality Organization and Despair.

Authors:  Jürgen Fuchshuber; Michaela Hiebler-Ragger; Adelheid Kresse; Hans-Peter Kapfhammer; Human F Unterrainer
Journal:  Front Psychiatry       Date:  2018-07-16       Impact factor: 4.157

8.  Unmet challenges in treating hypertension in patients with borderline personality disorder: A systematic review.

Authors:  Saara M Roininen; Marcus Cheetham; Beatrice U Mueller; Edouard Battegay
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

9.  A Network Perspective on the Comorbidity of Personality Disorders and Mental Disorders: An Illustration of Depression and Borderline Personality Disorder.

Authors:  Annemarie C J Köhne; Adela-Maria Isvoranu
Journal:  Front Psychol       Date:  2021-07-06

10.  Effects of substance use disorder on treatment process and outcome in a ten-session psychiatric treatment for borderline personality disorder.

Authors:  Louise Penzenstadler; Stéphane Kolly; Stéphane Rothen; Yasser Khazaal; Ueli Kramer
Journal:  Subst Abuse Treat Prev Policy       Date:  2018-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.